zofenopril has been researched along with enalaprilat anhydrous in 6 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 1 (16.67) | 18.7374 |
| 1990's | 4 (66.67) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 1 (16.67) | 2.80 |
| Authors | Studies |
|---|---|
| Codd, R; Gotsbacher, MP; Roth, L | 1 |
| Cushman, DW; Dzwonczyk, S; Fung, W; Grover, GJ; Sleph, PG; Tobias, D; Wang, P | 1 |
| Cassidy, MM; Freedman, AM; Weglicki, WB | 1 |
| Kloner, RA; Przyklenk, K | 1 |
| Lawson, DL; Mehta, JL; Saldeen, K | 1 |
| de Langen, CD; Scholtens, E; Tio, RA; van Gilst, WH; van Wijngaarden, J; Wesseling, H | 1 |
6 other study(ies) available for zofenopril and enalaprilat anhydrous
| Article | Year |
|---|---|
Immobilized Metal Affinity Chromatography as a Drug Discovery Platform for Metalloenzyme Inhibitors.
Topics: Chromatography, Affinity; Coordination Complexes; Crystallography, X-Ray; Dose-Response Relationship, Drug; Drug Discovery; Humans; Imino Acids; Metalloproteins; Metals, Heavy; Models, Molecular; Molecular Structure; Structure-Activity Relationship | 2020 |
Effects of different angiotensin-converting enzyme (ACE) inhibitors on ischemic isolated rat hearts: relationship between cardiac ACE inhibition and cardioprotection.
Topics: Angiotensin-Converting Enzyme Inhibitors; Animals; Captopril; Coronary Disease; Drug Stability; Enalaprilat; Fosinopril; Heart; In Vitro Techniques; Male; Myocardium; Organophosphorus Compounds; Prodrugs; Proline; Pyrroles; Ramipril; Rats; Rats, Inbred Strains; Sulfhydryl Compounds | 1991 |
Captopril protects against myocardial injury induced by magnesium deficiency.
Topics: Analysis of Variance; Animals; Antihypertensive Agents; Captopril; Cardiomyopathies; Cricetinae; Diagnosis, Computer-Assisted; Enalaprilat; Magnesium Deficiency; Male; Myocardium | 1991 |
Angiotensin converting enzyme inhibitors improve contractile function of stunned myocardium by different mechanisms of action.
Topics: Angiotensin-Converting Enzyme Inhibitors; Animals; Antioxidants; Captopril; Coronary Circulation; Dogs; Enalaprilat; Indomethacin; Myocardial Contraction; Myocardial Reperfusion Injury; Prostaglandins; Sulfhydryl Compounds | 1991 |
Angiotensin converting enzyme inhibitors potentiate the vasorelaxant effect of fibrinogen-derived peptide 6A.
Topics: Amino Acid Sequence; Angiotensin-Converting Enzyme Inhibitors; Animals; Aorta; Captopril; Drug Synergism; Enalaprilat; Fibrin Fibrinogen Degradation Products; In Vitro Techniques; Molecular Sequence Data; Rats; Vasodilation | 1991 |
The increase in coronary flow induced by converting enzyme inhibitors is prostacyclin independent.
Topics: 6-Ketoprostaglandin F1 alpha; Angiotensin-Converting Enzyme Inhibitors; Animals; Bradykinin; Captopril; Coronary Circulation; Enalaprilat; Epoprostenol; In Vitro Techniques; Indomethacin; Male; Rats; Rats, Inbred Strains | 1989 |